{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:49:31Z","timestamp":1783748971323,"version":"3.55.0"},"reference-count":6,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":5706,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p>As a practical strategy for reducing agitation in schizophrenia, low-potency neuroleptics have been commonly used as an adjunct in combination with high-potency neuroleptics that seem superior in reducing positive symptoms. There is no evidence, however, that giving more than one antipsychotics at a time enhances therapeutic effects. Antipsychotic polypharmacy has been rather considered an unproven and potentially harmful practice [4].<\/jats:p><jats:p>The low-potency neuroleptic levomepromazine has been in common use for agitated patients with schizophrenia in Europe and Japan [2,3], because of its markedly sedative property. In order to clarify whether levomepromazine as an adjunct to high-potency neuroleptics are beneficial or harmful, therefore, we compared the efficacy of the combined therapy with levomepromazine and high-potency neuroleptic haloperidol with the monotherapy with haloperidol for patients with acute exacerbation of schizophrenia.<\/jats:p>","DOI":"10.1016\/j.eurpsy.2004.07.001","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T17:17:28Z","timestamp":1093972648000},"page":"380-381","source":"Crossref","is-referenced-by-count":17,"title":["Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia"],"prefix":"10.1017","volume":"19","author":[{"given":"Masato","family":"Higashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800010488_ref6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0028-3908(77)90023-5","article-title":"Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain","volume":"16","author":"Peroutka","year":"1977","journal-title":"Neuropharmacology"},{"key":"S0924933800010488_ref5","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"S0924933800010488_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006912"},{"key":"S0924933800010488_ref2","first-page":"35","article-title":"A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia","volume":"53","author":"Ito","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"key":"S0924933800010488_ref1","first-page":"41","article-title":"Blood concentration and clinical effects of haloperidol therapy in combination with levomepromazine","volume":"5","author":"Hayashi","year":"1983","journal-title":"Jpn J Neuropsychop-harmacol"},{"key":"S0924933800010488_ref3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0447.1993.tb03391.x","article-title":"Levomepromazine receptor binding profile in human brain\u2014implications for treatment-resistant schizophrenia","volume":"87","author":"Lal","year":"1993","journal-title":"Acta Psychiatr Scand"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804001804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804001804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800010488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T08:01:24Z","timestamp":1601539284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800010488\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0924933800010488"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2004.07.001","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}